Increasing Complexity of Vaccine Development

Journal of Infectious Diseases

Volumn 212, Issue , 2015, Pages S12-S16

  Plotkin, Stanley A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Correlates of protection; Cytomegalovirus; Dengue; HIV; Immune memory; Influenza; Pertussis; Respiratory syncytial virus; Rotavirus

Indexed keywords

CYTOMEGALOVIRUS VACCINE; DENGUE VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; ROTAVIRUS VACCINE; VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; CYTOMEGALOVIRUS INFECTION; DENGUE; DRUG EFFICACY; DRUG RESEARCH; HIGH RISK PATIENT; HUMAN; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; INFLUENZA VACCINATION; INFLUENZA VIRUS; LOW RISK PATIENT; NONHUMAN; PRIORITY JOURNAL; ROTAVIRUS INFECTION; TROPICS; VACCINE PRODUCTION; VIRUS STRAIN; ACQUIRED IMMUNODEFICIENCY SYNDROME; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INFLUENZA, HUMAN; TRENDS; WHOOPING COUGH;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ALLERGY AND IMMUNOLOGY; HUMANS; IMMUNOLOGIC MEMORY; INFLUENZA, HUMAN; VACCINES; WHOOPING COUGH;

EID: 84937393983     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu568     Document Type: Conference Paper

References (45)

1. van Panhuis WG, Grefenstette J, Jung SY, et al. Contagious diseases in the United States from 1888 to the present. N Engl J Med 2013; 369:2152-8.
2. Plotkin ST, Plotkin SA. A short history of vaccination. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 6th ed. Philadelphia, PA: Elsevier/Saunders, 2013:1-13.
3. Lee BY, Shah M. Prevention of influenza in healthy children. Expert Rev Anti Infect Ther 2012; 10:1139-52.
4. McElhaney JE, Coler RN, Baldwin SL. Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults. Expert Rev Vaccines 2013; 12:759-66.
5. DiazGranados CA, Denis M, Plotkin S. Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. Vaccine 2012; 31:49-57.
6. Pica N, Palese P. Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med 2013; 64:189-202.
7. Clark TA, Messonnier NE, Hadler SC. Pertussis control: time for something new? Trends Microbiol 2012; 20:211-3.
8. Plotkin SA. The pertussis problem. Clin Infect Dis 2014; 58:830-3.
9. Mascola JR, Haynes BF. HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev 2013; 254:225-44.
10. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-20.
11. Robb ML, Rerks-Ngarm S, Nitayaphan S, et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis 2012; 12:531-7.
12. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366:1275-86.
13. Yates NL, Liao HX, Fong Y, et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med 2014; 6:228ra39.
14. Excler JL, Ake J, Robb ML, Kim JH, Plotkin SA. Nonneutralizing functional antibodies: a new 'old' paradigm for HIV vaccines. Clin Vaccine Immunol 2014; 21:1023-36.
15. Vesikari T. Rotavirus vaccination: a concise review. Clin Microbiol Infect 2012; 18(suppl 5):57-63.
16. Cherian T, Wang S, Mantel C. Rotavirus vaccines in developing countries: the potential impact, implementation challenges, and remaining questions. Vaccine 2012; 30(suppl 1):A3-6.
17. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012; 380:1559-67.
18. Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011; 29: 7229-41.
19. Barban V, Munoz-Jordan JL, Santiago GA, et al. Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric yellow fever 17D/dengue viruses. Virology 2012; 429:91-8.
20. Rey FA. Dengue virus: two hosts, two structures. Nature 2013; 497:443-4.
21. Adler SP. Immunization to prevent congenital cytomegalovirus infection. Br Med Bull 2013; 107:57-68.
22. Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis 2004; 39:233-9.
23. Griffiths P, Plotkin S, Mocarski E, et al. Desirability and feasibility of a vaccine against cytomegalovirus. Vaccine 2013; 31(suppl 2):B197-203.
24. Plotkin SA, Starr SE, Friedman HM, Gonczol E, Brayman K. Vaccines for the prevention of human cytomegalovirus infection. Rev Infect Dis 1990; 12(suppl 7):S827-38.
25. Adler SP, Starr SE, Plotkin SA, et al. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 1995; 171:26-32.
26. Plotkin SA, Higgins R, Kurtz JB, et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 1994; 58:1176-8.
27. Gonczol E, Ianacone J, Ho WZ, Starr S, Meignier B, Plotkin S. Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers. Vaccine 1990; 8:130-6.
28. Pass RF, Duliege AM, Boppana S, et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 1999; 180:970-5.
29. Pass RF, Zhang C, Evans A, et al. Vaccine prevention of maternal cyto-megalovirus infection. N Engl J Med 2009; 360:1191-9.
30. Griffiths PD, Stanton A, McCarrell E, et al. Cytomegalovirus glycopro-tein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011; 377:1256-63.
31. Wang D, Shenk T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci U S A 2005; 102:18153-8.
32. Wang D, Yu QC, Schroer J, Murphy E, Shenk T. Human cytomegalo-virus uses two distinct pathways to enter retinal pigmented epithelial cells. Proc Natl Acad Sci U S A 2007; 104:20037-42.
33. Fu TM, An Z, Wang D. Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease. Vaccine 2014; 32:2525-33.
34. McLellan JS, Chen M, Joyce MG, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 2013; 342:592-8.
35. Kim E, Okada K, Beeler JA, et al. Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, im-munogenicity, and enhanced disease in a cotton rat model. J Virol 2014; 88:5100-8.
36. Rappuoli R. Conjugates and reverse vaccinology to eliminate bacterial meningitis. Vaccine 2001; 19:2319-22.
37. Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 2006; 103:10834-9.
38. Vogel U, Taha MK, Vazquez JA, et al. Predicted strain coverage of a me-ningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 2013; 13:416-25.
39. Hokey DA, Ginsberg A. The current state of tuberculosis vaccines. Hum Vaccin Immunother 2013; 9:2142-6.
40. Tameris M, Geldenhuys H, Luabeya AK, et al. The candidate TB vaccine, MVA85A, induces highly durable Th1 tesponses. PLoS One 2014; 9:e87340.
41. Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013; 381:1021-8.
42. Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A. From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum Vaccin 2010; 6:90-6.
43. Riley EM, Stewart VA. Immune mechanisms in malaria: new insights in vaccine development. Nat Med 2013; 19:168-78.
44. Seder RA, Chang LJ, Enama ME, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 2013; 341:1359-65.
45. Campo JJ, Sacarlal J, Aponte JJ, et al. Duration of vaccine efficacy against malaria: 5th year of follow-up in children vaccinated with RTS,S/AS02 in Mozambique. Vaccine 2014; 32:2209-16.